A Comparison Between GUMMETAL and SS Orthodontic Wires in Space Closure
A Comparison Between TiNbTaZr (GUMMETAL) and Stainless-steel Alloy for Space Closure With Sliding Mechanics A Pilot Randomized Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14214
- University at Buffalo
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Full permanent dentition (except third molars)
- Good general and oral health
- Bilateral spaces 3 >/= mm distal to the maxillary canines
- Normal and hypodivergent growth pattern
- Any dental malocclusion
- Good Oral Hygiene
Exclusion Criteria:
- Systemic diseases or syndrome
- Abnormalities in teeth size and/or shape
- Previous orthodontic treatment
- Anti-inflammatory medication
- Craniofacial anomalies
- Hyperdivergent growth pattern
- Periodontal disease / attachment loss exceeding 25% of root length
- Significant pre or in-treatment root resorption
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: GUMMETAL TiNbTaZr
TiNbTaZr (Beta-Titanium) Alloy used to manufacture orthodontic archwires.
We will be using an archwire with the size of 0.016 x 0.022"
|
Orthodontic archwire made of TiNbTaZr alloy.
Other Names:
|
|
Active Comparator: Stainless Steel (CrNi)
Stainless steel (18% Chromium and 8% Nickel) used as the control, and linked anteriorly to the GUMMETAL counterpart.
Size of archwire is 0.016 x 0.022"
|
Stainless steel (18% Chromium and 8% Nickel) used as the control, and linked anteriorly to the GUMMETAL counterpart.
Size of archwire is 0.016 x 0.022"
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Amount of Canine Retraction
Time Frame: 12 weeks
|
Canine movement measured at distal marginal ridge
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
3-Dimensional Control of Canine Movement Assessment
Time Frame: 12 weeks
|
Canine position (tip, rotation, angulation) will be assessed from initial to final position
|
12 weeks
|
|
Rate of Canine Retraction Per Month
Time Frame: 12 weeks
|
Rate of canine retraction in mm per month
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Thikriat Al-Jewair, University at Buffalo
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GMTSS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.